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Background. A number of different treatment approaches have been recommended for the treatment of venous ulceration,
including local ulcer treatment, compression and drug therapy. Recent advances in tissue engineering have resulted in
living tissues being developed for cutaneous wound repair and skin replacement. The aim of this pilot study was to compare
the rate of healing of venous ulcers in patients treated with Dermagraft (a human fibroblast-derived dermal replacement) and
compression therapy or compression therapy alone.
Methods. A total of 18 patients with venous ulceration of the leg were recruited into the pilot study. Ten patients were
treated with Dermagraft and compression therapy, and eight patients were treated with compression therapy alone. Healing
was assessed by ulcer tracing and computerised planimetry. Skin perfusion was measured by laser Doppler.
Results. Five (50%) of the patients treated with Dermagraft and one (12.5%) control patient had healed by the end of the
12-week study period (NS). The total ulcer area rate of healing and linear rate of healing was significantly improved in
patients treated with Dermagraft (P ¼ 0.001 and P ¼ 0.006, respectively, Mann–Whitney U-test). The number of
capillaries increased in both the treatment and control group. Peri-ulcer skin perfusion increased by 20% in patients treated
with Dermagraft, compared with 4.9% in the control group.
Conclusion. The data from this small pilot study suggests that Dermagraft is associated with improved healing of venous
ulceration. Following this pilot study, further clinical studies are needed to confirm the validity of these results in ‘hard to
heal’ venous leg ulcers.
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Introduction
Various approaches have been recommended for the
treatment of venous ulceration. These include com-
pression therapy, local ulcer treatment, drug therapy
and surgery, which are reported in the literature with
differing results. Compression bandaging is still the
mainstay of venous ulcer treatment, and is frequently
used in conjunction with advanced wound dressings1,2
with 3-month healing rates of between 69 and 74% in
patients treated in specialised clinics.3 The healing
rates reported in community treated patients range
between 52 and 73%.4 A variety of prognostic factors
also influence the success of compression bandaging,
including size and duration of ulcer.5 Fibrinolytic
drugs, intended to treat fibrosis, e.g. stanazolol and
pentoxifylline, or drugs which inhibit white cell
activation in the microcirculation, e.g. methylxan-
thines and prostaglandin E16,7 are also used to manage
venous ulceration. Other pharmacological therapies
include zinc, phlebotrophic agents such as hydroxy-
rutoside and calcium dobesilate, haemorheologic
agents such as pentoxifylline and aspirin.8 Surgical
intervention to treat the malfunctioning veins of the
lower limb and/or operations involving the ulcer
itself, such as skin grafting, have also been recom-
mended.9,10 In principle, correcting superficial vein
insufficiency or perforating vein outflow should be
done early. Deep vein reconstruction by stenting, by-
pass or valvuloplasty should be performed only when
all other forms of treatment have failed, because of the
major complications associated with these reconstruc-
tive procedures. Such complications include deep vein
thrombosis (DVT) and pulmonary embolism, as well
as ulcer recurrence should the procedures fail.8 Skin
grafting should be reserved for cases in which there is
failure to heal after 12 months of properly applied
support or compression bandaging, because skin
grafting when used as an isolated procedure results
in high rates of recurrence.11
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The prevalence of venous ulcers in the US is
estimated at 500,000–600,000 (i.e. 1.5–2 per 100,000
individuals), increases with age. Estimates of the
annual incidence of leg ulcer in the UK and Switzer-
land are 3.5 and 0.2 per 1000 individuals, respect-
ively.12 Treatment of venous ulcers can be expensive,
leading to a large economic burden on health services
in many countries. However, comprehensive studies
on the economic costs of venous ulcers are lacking. In a
study conducted in the United States, the average total
medical cost per patient was $9685 (median: $3036).
Home health care, hospitalisations and home dressing
changes accounted for 48, 25 and 21% of total costs,
respectively.13 Time absent from work, forced early
retirement, loss of functional independence and
unquantifiable suffering may be additional factors
that contribute to the overall burden of venous ulcers.
Over the past decade, the field of tissue engineering
has grown rapidly, and living tissues have become
available for cutaneous wound repair and skin
replacement. Dermagraftw (Smith and Nephew Plc)
is a human fibroblast-derived dermal replacement for
wound repair. The origin of the cells is human
newborn foreskin.14,15 It consists of a bio-absorbable
three-dimensional scaffold containing growth factors,
matrix proteins and glycosaminoglycans, on which
fibroblasts are cultured to produce a living, metabo-
lically active dermal tissue.16 Dermagraft degrades by
hydrolysis, leaving the cellular and extracellular
components, which act in the wound bed and
encourage epithelialisation from the periphery. Der-
magraft implants have been clinically studied for over
10 years and like other allogenic dermal implants have
not demonstrated rejection.17 Maintenance of safety,
tissue integrity, functionality and viability from pro-
duct manufacture to end use has been accomplished
through innovation in design of both tissue growth
and preservation processes. Skin replacement pro-
ducts are the most advanced, and several tissue-
engineered care materials have been on the market in
the USA and in several other countries for some years.
Risks associated with the use of such technologies are
low.18 The dermal layer of skin offers many potential
advantages as a therapeutic implant. Fibroblasts do
not carry surface antigens (HLA-DR) as do epidermal
cells that can result in allograft rejection. Implantation
of allogenic dermal tissue does not stimulate an
immune response. Kern and colleagues19 have proposed
that interaction of fibroblasts with the fibroblast-
derived extracellular matrix is an important modu-
lator of gamma-interferon responsiveness, and that
this interaction may play a role in the low immuno-
genicity of allogeneic fibroblasts grown on scaffolds.
This mechanism of action being responsible for the
lack of rejection associated with the use of Dermagraft.
Dermagraft was initially introduced for the treatment
of chronic wounds, such as diabetic foot ulcers,20,21
and clinical trials have shown that Dermagraft heals
such ulcers more rapidly than conventional therapy
alone.22 – 28 Although the precise mechanisms by
which Dermagraft affects chronic wounds and
improves healing are not yet established, a study
comparing Dermagraft to saline-moistened gauze
reported significantly more chronic ulcers healed in
the Dermagraft group than in the control group (71.4%
versus 14.3%, P ¼ 0:003) at week 12.29 This study also
reported that Dermagraft patients achieved wound
closure significantly faster than control patients ðP ¼
0:004Þ; and the percent of patients who experienced an
infection involving their study wound was also less.
These findings were reproduced in a recent study of
patients with diabetic foot ulcers of .6 weeks’
duration, with 30% (39 of 130) of Dermagraft patients
healed compared with 18% (21 of 115) of control
patients ðP ¼ 0:023Þ after 12 weeks’ treatment.30 The
primary objective of treating venous ulceration is to
achieve complete healing. Accurate measurement of
initial ulcer size and rate of healing is important in the
assessment of any treatment regimen. Different
methods have been described for the measurement
of ulcer size, including measurement of the two
maximal perpendicular diameters of the ulcer using
a transparent ruler, direct ulcer tracing with digital
planimetry and non-invasive, three-dimensional laser
imaging.31 – 34 Digital planimetry has been shown in
clinical studies to be a reliable and valid method for
the assessment of wound size and rate of healing.35,36
The current pilot study compared the efficacy of
Dermagraft when used in combination with four-layer
compression bandaging (ProForew, Smith and
Nephew Plc) and four-layer compression bandaging
used alone. Using a randomised, prospective, con-
trolled design, the pilot study aimed to confirm
whether the addition of Dermagraft to four-layer
compression therapy improved venous ulcer healing.
Patients presenting with ulcers between 3 and 25 cm2
and of more than 12 weeks’ duration were considered
eligible for inclusion. The study also investigated the
cutaneous blood flow changes and the histological
findings associated with venous leg ulcers treated with
Dermagraft.
Patients and Methods
A total of 18 patients were recruited into this single-
centre pilot study. The trial protocol was approved by
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Leeds General Infirmary’s Ethics Committee, and
informed consent was obtained from all participants.
All patients had chronic venous leg ulcers of more
than 12 weeks’ duration at the time of presentation,
and an ulcer area range of 3–25 cm2. Venous leg ulcers
were selected after clinical examination, duplex finding
of venous dysfunction (all patients had evidence of
superficial reflux, but no deep venous reflux or
evidence of DVT), and by exclusion of other causes
of ulceration, especially arterial insufficiency (ankle-
brachial pressure index (ABPI) .0.9).
All ulcers entered into the study were clean and the
ulcer bed had healthy granulation tissue. Before
treatment, ulcers were cleaned with cleansing agents,
de-sloughing materials, or occasionally by superficial
curettage after application of topical anaesthetics.
Protocol-eligible patients were prospectively random-
ised to treatment (Dermagraft or control) according to
a computer-generated code based on the order of
admittance to the study.
Patients randomised to the Dermagraft group
received Dermagraft at weeks 0, 1, 4 and 8 in addition
to four-layer compression bandaging. Control patients
were treated with a local non-adherent dressing
(Dermanet, Smith and Nephew Plc and four-layer
compression bandaging. Four-layer compression ban-
daging was applied by a trained member of staff. All
patients were followed up weekly to 12 weeks on an
outpatient basis. Twelve weeks was chosen as the
endpoint for the study to mirror other clinical series
reported in the literature, and as a period of time in
which follow-up was feasible. Complete healing was
defined as complete epithelialisation with no exudates
drainage.
Assessment of healing
Healing was assessed weekly by means of direct ulcer
tracing onto clear plastic sheet and computerised
planimetry. Ulcer measurement was performed by a
clinician blinded to the treatment group. All ulcers
were observed until healed, or until the end of the
study at 12 weeks. Healing was calculated by
subtracting the final ulcer area from the initial area
and dividing by the number of weeks that the patient
had been observed to obtain the total area healed per
week.
Peri-ulcer cutaneous blood flow measurement
Peri-ulcer skin blood flow (SBF) was measured weekly
for 12 weeks by laser Doppler flowmetry, Oxford
Arraye (Oxford Optronix, Oxford, England) using the
appropriate surface probes. Eight readings from eight
different sites were recorded and an average calcu-
lated. The first reading at week 0 was considered to
represent the initial SBF. The average of the last two
readings represented the end-study SBF, regardless of
the type of treatment provided.
Histological examination
At the beginning of treatment, an initial 6 mm punch
biopsy was taken from each ulcer base. A second
biopsy was taken from each ulcer at week 6 if the ulcer
had not healed by that time. Biopsies were fixed in
formalin, dehydrated and embedded in paraffin wax.
Five sections were cut at 4m and stained with
conventional haematoxylin and eosin (H&E). The
number of capillaries was counted in the biopsies
obtained at weeks 0 and 6. The average number of
capillaries was obtained by applying a grid to two
different microscopic fields of five H&E stained
sections, where two independent investigators
counted the capillaries.
Study completion
Patients completed the study if the ulcer had healed, or
if they had participated in the study for 12 weeks.
Statistical analysis
The pilot study was not powered for significance due
to the constraints of time. The statistical advisor for the
study calculated that 132 patients would be needed to
achieve significance at the 5% level (personal com-
munication, Mr Mark Airey, University of Leeds).
Recruitment of this number of patients was not
possible with the constraints on patient numbers in a
single-centre study.
Healing outcome was assessed by Fisher’s exact
test. The percentage reduction in ulcer area was
compared between the treatment groups with the
Mann–Whitney U-test. The total ulcer area rate of
healing was compared between treatment groups
using a two-sample t-test. The total amount of linear
healing was calculated for each patient using Gilman’s
equation37 as:
Initial area2 final area
ðInitial perimeter þ final perimeterÞ=2
This was divided by the number of weeks in the study
to give the linear healing per week. Change in SBF and
the average number of capillaries (final 2 initial
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value) was calculated for each patient and compared
between the treatment groups using the Mann–
Whitney U-test (95% CI).
Results
A total of 18 patients were randomised: 10 were
treated with Dermagraft in addition to four-layer
compression bandaging and eight with four-layer
compression bandaging alone. The patients were
well matched at randomisation with respect to
demographics and mean ulcer duration (Table 1),
there were no significant differences between the two
groups.
Five (50%) of the patients treated with Derma-
graft and one (12.5%) control patient had healed by
the end of the 12-week study. The difference
between the two groups was not statistically
significant ðP ¼ 0:15Þ: However, there was a statisti-
cally significant difference between the Dermagraft
and control groups ðP ¼ 0:002Þ with respect to the
reduction in ulcer area. Fig. 1 shows the mean ulcer
area at initial and final assessment and the
percentage reduction in ulcer area. The mean initial
ulcer area in the Dermagraft group was 9.5 cm2 (SD
4.2). The mean initial ulcer area in the control group
was 12 cm2 (SD 7.6). The mean percentage reduction
for the Dermagraft-treated patients was 84% (SD 22)
and for the control group 16% (SD 43). Fig. 2 shows
the mean ulcer area at weeks 0 and 12.
The total ulcer area rate of healing was normally
distributed between treatment groups (Table 2).
There was a statistically significant difference in
the total ulcer rate of healing between Dermagraft
and the control groups ðP ¼ 0:001Þ: The mean total
ulcer area rate of healing for Dermagraft was
0.82 cm2/week (SD 0.33) and for the control group
0.15 cm2/week (SD 0.39).
The linear rate of healing for both groups is
shown in Fig. 3. The mean linear rate of healing for
the Dermagraft-treated patients was 0.14 cm/week
(SD 0.08), and for control patients 0.033 cm/week
(SD 0.085). This difference was statistically signifi-
cant ðP ¼ 0:006Þ: As the study was concluded at
week 12 no data are available on the maintenance of
healing.
Fig. 4 shows the initial and final values for SBF for
the two groups. The mean initial SBF for the
Dermagraft patients was 125 blood perfusion units
(BPU) (SD 40) and for the control patients the mean
SBF was 122 BPU (SD 37). Patients treated with
Dermagraft had a greater increase (25%) in SBF from
initial to final assessment than the control group
(8.5%), but this difference between the two groups was
not statistically significant ðP ¼ 0:36Þ: The mean
 
Fig. 1. Mean ulcer area at initial and final assessment.
Table 1. Patient demographics
Dermagraft
ðn ¼ 10Þ
Control
ðn ¼ 8Þ
Mean age (y) 58 62
Age range (y) 44–65 54–77
Sex
Male 6 5
Female 4 3
Mean ulcer duration (weeks) 118.8 120
Ulcer duration (weeks) 12–192 24–288
Mean ulcer area (cm2) 9.5 12.3
Ulcer area (cm2) 3.1–17.6 5.4–24.7
ABPI 1.02 1.1
Fig. 2. Mean ulcer area before treatment and at week 12.
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increase in SBF for the Dermagraft patients was 25
BPU (SD 43) and the mean increase in SBF for the
control group was 6.1 BPU (SD 33).
Capillary count in histological sections did not
reveal significant changes in either group. The mean
change in the average number of capillaries (final 2
initial value) for the Dermagraft patients was an
increase of 2.9 (SD 5.5) and for the control patients
was an increase of 2.1 (SD 3.2)—this was not
statistically significant ðP ¼ 0:55Þ:
Discussion
The healing of venous leg ulcers is a complex process,
and different treatment regimens are available to
facilitate this process. Tissue engineering offers the
possibility of replacing the damaged or destroyed
dermis of patients suffering from a deep ulcer with a
living human fibroblast-derived dermal implant. In
this study, Dermagraft was used as an adjunct to
compression therapy. The precise mechanism by
which Dermagraft stimulates chronic wounds to heal
has not yet been established. Possible mechanisms
include providing the wound bed with a metabolically
active dermal matrix and/or promoting the
expression of important mediators (VEGF, TGF-b,
HGF/SF) and thus stimulating angiogenesis and
subsequent wound healing.16,38
In this study, measurements of both the total ulcer
healing rate (which could be influenced by the initial
size and shape of the ulcer) and the linear healing of
the ulcer edge (incorporating the initial ulcer area and
perimeter) were used in order to reflect the true healing
rates of the ulcers. Despite the limitation of a small
sample size, the percentage reduction in ulcer area was
significantly higher in the Dermagraft treated patients
ðP ¼ 0:002Þ during the 12-week study period. The
median percentage reduction was 95 and 17%,
respectively. The difference between these healing
rates could be explained by the initial ulcer size (and
shape) in the Dermagraft and control groups, 9.5 and
12 cm2, respectively. The larger initial ulcer size in the
control group may explain this groups’ poor results
when compared with other published studies,
Table 2. Total ulcer area rate of healing
Area heal per week (cm2/week) Dermagraft
ðn ¼ 10Þ
Control
ðn ¼ 8Þ
Total
ðn ¼ 18Þ
Healed ulcers Mean 1.01 0.92 1.00
Median 1.01 0.92 0.97
SD 0.27 – 0.25
Minimum 0.750 0.917 0.750
Maximum 1.420 0.917 1.420
n 5 1 6
Positively healing (reduced in area) Mean 0.64 0.18 0.41
Median 0.64 0.17 0.34
SD 0.29 0.12 0.32
Minimum 0.31 0.083 0.083
Maximum 1.075 0.376 1.075
n 5 5 10
Non-healing (increased in area) Mean – 20.32 20.32
Median – 20.32 20.32
SD – 0.003 0.003
Minimum – 20.317 20.317
Maximum – 20.313 20.313
n 0 2 2
Fig. 3. Linear rate of healing by Gilmans’s equation
ðD ¼ DA=PÞ, where D; linear healing; A; change in area; P;
mean perimeter of the initial and final ulcers.
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although a Cochrane review reported a wide varia-
bility in healing rates (40–84%) with compression
bandaging in the treatment of venous leg ulcers.39 The
initial ulcer size and shape can have a great effect on
calculating the total area healed over time, where
small ulcers may heal more quickly than large ulcers,
producing misleading results when comparing rates
of healing. However, the linear healing of the wound
edge is not affected by the initial ulcer geometry.
Linear healing incorporates the ulcer size and per-
imeter in the calculation, and gives a more accurate
representation of the rate of healing of an ulcer. In this
study, there was a statistically significant difference
between the Dermagraft and control groups ðP ¼
0:006Þ in the linear rate of healing.
Actions of Dermagraft in wound repair include
colonisation by cells and provision of growth factors
and cytokines, both activities dependent on living
cells. Low fibroblast proliferative potential has been
reported in venous stasis ulcers.40 Studies have shown
that proliferation can be stimulated by fibroblast
growth factor (FGF) and epidermal growth factor to
a significant extent in these ulcers.40 In a study of
Dermagraft in the treatment of diabetic foot ulcers,
Mansbridge et al.41 found that cells in the cryopre-
served culture showed 60% viability by dye exclusion
and, when isolated, were able to proliferate in
monolayer culture. Protein synthesis by Dermagraft
was inhibited 70–98% by cryopreservation, but, if
within the therapeutic range, recovered to 45–85% of
the prefreeze value over 48 h. More recently, Newton
and co-workers42 found that blood flow at the base of
diabetic foot ulcers increased in patients treated with
Dermagraft. These data demonstrate the critical
dependence of the therapeutic properties of this living
dermal implant on recovery of protein synthesis,
growth factor expression, and angiogenesis, deter-
mined by metabolic activity.41 Growth factor secretion
is a function of live cells, so the ability of live
fibroblasts in implants to colonise wound beds is of
great importance. Cells derived from a single implan-
tation of Dermagraft were identified by Mansbridge
and colleagues43 in female patients by detection of SRY
using nested polymerase chain reaction (PCR) were
detected up to 6 months (the longest time-point
tested), indicating they were able to colonise the
wound bed and survive the host environment.
Angiogenesis is an essential part of the usual
process of healing.44 This process requires the
migration and proliferation of endothelial cells in
order for new functioning blood vessels to form.
Growth factors also play a major role in regulating the
overall process of angiogenesis.45 Our results showed
a considerable mean increase in peri-ulcer skin
perfusion in the Dermagraft group (20%) compared
with the control group (4.9%). Dermagraft treated
patients also had a greater increase in SBF from the
initial to the final assessment, although this difference
was not statistically significant ðP ¼ 0:36Þ: The median
increase in SBF was also higher in the Dermagraft
group, 22 BPU versus 8.5 BPU in the control arm of the
study. This increase in peri-ulcer skin perfusion may
reflect an early stimulation of angiogenesis and
subsequent blood vessel formation. However, further
studies are required to confirm these findings.
The data from this pilot study suggests that
Dermagraft may expedite the healing of chronic
venous leg ulcers. These initial results may form a
basis for future clinical investigations and justify the
conduct of a larger study with prolonged follow up to
confirm their validity, such a study is currently being
planned.
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